Hedgehog Signaling: From Basic Biology to Cancer Therapy

Cell Chemical Biology

Volumn 24, Issue 3, 2017, Pages 252-280

  Wu, Fujia ^a,b   Zhang, Yu ^a   Sun, Bo ^a   McMahon, Andrew P ^c   Wang, Yu ^a,b  

^a INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

basal cell carcinoma; cancer therapy; cholesterol; drug resistance; endogenous smoothened regulation; GLI; hedgehog signaling; medulloblastoma; smoothened; stem cell

Indexed keywords

CHOLESTEROL; OXYSTEROL; PHOSPHATIDYLINOSITOL 4 PHOSPHATE; PROTEIN INHIBITOR; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; ANTINEOPLASTIC AGENT; KRUPPEL LIKE FACTOR; PHOSPHATIDYLINOSITOL 4-PHOSPHATE; POLYPHOSPHOINOSITIDE;

ALLOSTERISM; CANCER THERAPY; GENERAL ASPECTS OF DISEASE; HUMAN; LEUKEMIA; MALIGNANT NEOPLASM; NONHUMAN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; AGONISTS; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CILIUM; DRUG EFFECT; METABOLISM; MOLECULAR LIBRARY; NEOPLASM; PATHOLOGY; PHARMACOLOGY;

ANTINEOPLASTIC AGENTS; CILIA; HEDGEHOG PROTEINS; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; NEOPLASMS; OXYSTEROLS; PHOSPHATIDYLINOSITOL PHOSPHATES; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES; SMOOTHENED RECEPTOR;

EID: 85014701373     PISSN: 24519456     EISSN: 24519448     Source Type: Journal    
DOI: 10.1016/j.chembiol.2017.02.010     Document Type: Review

References (234)

1. Aanstad, P., Santos, N., Corbit, K.C., Scherz, P.J., Trinh, L.A., Salvenmoser, W., Huisken, J., Reiter, J.F., Stainier, D.Y.R., The extracellular domain of smoothened regulates ciliary localization and is required for high-level Hh signaling. Curr. Biol. 19 (2009), 1034–1039.
2. Adolphe, C., Hetherington, R., Ellis, T., Wainwright, B., Patched1 functions as a gatekeeper by promoting cell cycle progression. Cancer Res. 66 (2006), 2081–2088.
3. Ally, M.S., Ransohoff, K., Sarin, K., Atwood, S.X., Rezaee, M., Bailey-Healy, I., Kim, J., Beachy, P.A., Chang, A.L., Oro, A., et al. Effects of combined treatment with arsenic trioxide and itraconazole in patients with refractory metastatic basal cell carcinoma. JAMA Dermatol. 152 (2016), 452–456.
4. Amakye, D., Robinson, D., Rose, K., Cho, J., Ligon, K.L., Sharp, T., Haider, A., Bandaru, R., Ando, Y., Geoerger, B., et al. Abstract 4818: the predictive value of a 5-gene signature as a patient pre-selection tool in medulloblastoma for Hedgehog pathway inhibitor therapy. Cancer Res., 72, 2012, 4818.
5. Amakye, D., Jagani, Z., Dorsch, M., Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat. Med. 19 (2013), 1410–1422.
6. Antonarakis, E.S., Heath, E.I., Smith, D.C., Rathkopf, D., Blackford, A.L., Danila, D.C., King, S., Frost, A., Ajiboye, A.S., Zhao, M., Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist 18 (2013), 163–173.
7. Aszterbaum, M., Epstein, J., Oro, A., Douglas, V., LeBoit, P.E., Scott, M.P., Epstein, E.H. Jr., Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. Nat. Med. 5 (1999), 1285–1291.
8. Atwood, S.X., Li, M., Lee, A., Tang, J.Y., Oro, A.E., GLI activation by atypical protein kinase C iota/lambda regulates the growth of basal cell carcinomas. Nature 494 (2013), 484–488.
9. Atwood, S.X., Sarin, K.Y., Whitson, R.J., Li, J.R., Kim, G., Rezaee, M., Ally, M.S., Kim, J., Yao, C., Chang, A.L., et al. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell 27 (2015), 342–353.
10. Aza-Blanc, P., Lin, H.Y., Ruiz i Altaba, A., Kornberg, T.B., Expression of the vertebrate Gli proteins in Drosophila reveals a distribution of activator and repressor activities. Development 127 (2000), 4293–4301.
11. Bai, C.B., Auerbach, W., Lee, J.S., Stephen, D., Joyner, A.L., Gli2, but not Gli1, is required for initial Shh signaling and ectopic activation of the Shh pathway. Development 129 (2002), 4753–4761.
12. Bailey, J.M., Mohr, A.M., Hollingsworth, M.A., Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene 28 (2009), 3513–3525.
13. Barzi, M., Berenguer, J., Menendez, A., Alvarez-Rodriguez, R., Pons, S., Sonic-hedgehog-mediated proliferation requires the localization of PKA to the cilium base. J. Cell Sci. 123 (2010), 62–69.
14. Beauchamp, E.M., Ringer, L., Bulut, G., Sajwan, K.P., Hall, M.D., Lee, Y.C., Peaceman, D., Ozdemirli, M., Rodriguez, O., Macdonald, T.J., et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J. Clin. Invest. 121 (2011), 148–160.
15. Belani, C.P., Dahlberg, S.E., Rudin, C.M., Fleisher, M., Chen, H.X., Takebe, N., Ramalingam, S.S., Schiller, J.H., Three-arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either vismodegib (V) or cixutumumab (Cx) for patients with extensive stage-small cell lung cancer (ES-SCLC)(ECOG 1508). ASCO Annu. Meet. Proc., 31, 2013, 7508.
16. Bender, M.H., Hipskind, P.A., Capen, A.R., Cockman, M., Credille, K.M., Gao, H., Bastian, J.A., Clay, J.M., Lobb, K.L., Sall, D.J., Identification and characterization of a novel smoothened antagonist for the treatment of cancer with deregulated hedgehog signaling. Cancer Res., 71, 2011, 2819.
17. Berlin, J., Bendell, J.C., Hart, L.L., Firdaus, I., Gore, I., Hermann, R.C., Mulcahy, M.F., Zalupski, M.M., Mackey, H.M., Yauch, R.L., et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin. Cancer Res. 19 (2013), 258–267.
18. Berman, D.M., Karhadkar, S.S., Hallahan, A.R., Pritchard, J.I., Eberhart, C.G., Watkins, D.N., Chen, J.K., Cooper, M.K., Taipale, J., Olson, J.M., et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297 (2002), 1559–1561.
19. Berman, D.M., Karhadkar, S.S., Maitra, A., Montes De Oca, R., Gerstenblith, M.R., Briggs, K., Parker, A.R., Shimada, Y., Eshleman, J.R., Watkins, D.N., et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 425 (2003), 846–851.
20. Bijlsma, M.F., Spek, C.A., Zivkovic, D., van de Water, S., Rezaee, F., Peppelenbosch, M.P., Repression of smoothened by patched-dependent (Pro-)Vitamin D3 secretion. PLoS Biol. 4 (2006), 1397–1410.
21. Blassberg, R., Macrae, J.I., Briscoe, J., Jacob, J., Reduced cholesterol levels impair Smoothened activation in Smith-Lemli-Opitz syndrome. Hum. Mol. Genet. 25 (2016), 693–705.
22. Borzillo, G.V., Lippa, B., The Hedgehog signaling pathway as a target for anticancer drug discovery. Curr. Top. Med. Chem. 5 (2005), 147–157.
23. Bosco-Clement, G., Zhang, F., Chen, Z., Zhou, H., Li, H., Mikami, I., Hirata, T., Yagui-Beltran, A., Lui, N., Do, H., Targeting Gli transcription activation by small molecule suppresses tumor growth. Oncogene 33 (2014), 2087–2097.
24. Bryden, M.M., Evans, H.E., Keeler, R.F., Cyclopia in sheep caused by plant teratogens. J. Anat., 110, 1971, 507.
25. Buonamici, S., Williams, J., Morrissey, M., Wang, A., Guo, R., Vattay, A., Hsiao, K., Yuan, J., Green, J., Ospina, B., et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci. Transl. Med., 2, 2010, 3001599.
26. Burness, C.B., Sonidegib: first global approval. Drugs 75 (2015), 1559–1566.
27. Byrne, E.F., Sircar, R., Miller, P.S., Hedger, G., Luchetti, G., Nachtergaele, S., Tully, M.D., Mydock-McGrane, L., Covey, D.F., Rambo, R.P., et al. Structural basis of Smoothened regulation by its extracellular domains. Nature 535 (2016), 517–522.
28. Catenacci, D.V., Junttila, M.R., Karrison, T., Bahary, N., Horiba, M.N., Nattam, S.R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., et al. Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J. Clin. Oncol. 33 (2015), 4284–4292.
29. Chang, A.L., Oro, A.E., Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch. Dermatol. 148 (2012), 1324–1325.
30. Chavez, M., Ena, S., Van Sande, J., de Kerchove d'Exaerde, A., Schurmans, S., Schiffmann, S.N., Modulation of ciliary phosphoinositide content regulates trafficking and sonic hedgehog signaling output. Dev. Cell 34 (2015), 338–350.
31. Chen, J.K., Taipale, J., Cooper, M.K., Beachy, P.A., Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 16 (2002), 2743–2748.
32. Chen, J.K., Taipale, J., Young, K.E., Maiti, T., Beachy, P.A., Small molecule modulation of Smoothened activity. Proc. Natl. Acad. Sci. USA 99 (2002), 14071–14076.
33. Cheung, H.O., Zhang, X., Ribeiro, A., Mo, R., Makino, S., Puviindran, V., Law, K.K., Briscoe, J., Hui, C.C., The kinesin protein Kif7 is a critical regulator of Gli transcription factors in mammalian hedgehog signaling. Sci. Signal., 2, 2009, 2000405.
34. Chong, Y.C., Mann, R.K., Zhao, C., Kato, M., Beachy, P.A., Bifurcating action of Smoothened in Hedgehog signaling is mediated by Dlg5. Genes Dev. 29 (2015), 262–276.
35. Chu, Q.S., Mahipal, A., Schuler, M., De Braud, F.G.M., Dirix, L., Rampersad, A., Zhou, J., Wu, Y., Kalambakas, S., Wen, P.Y., 445ODOSE-ESCALATION study of sonidegib (LDE225) plus buparlisib (BKM120) in patients (PTS) with advanced solid tumors. Ann. Oncol. 25 (2014), iv147–iv148.
36. Cohen, D.J., Christos, P.J., Sparano, J.A., Kindler, H.L., Catenacci, D.V.T., Bekaii-Saab, T.B., Tahiri, S., Janjigian, Y.Y., Gibson, M.K., Chan, E., A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: a New York Cancer Consortium led study. ASCO Annu. Meet. Proc., 31, 2013, 67.
37. Cooper, M.K., Porter, J.A., Young, K.E., Beachy, P.A., Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 280 (1998), 1603–1607.
38. Cooper, M.K., Wassif, C.A., Krakowiak, P.A., Taipale, J., Gong, R., Kelley, R.I., Porter, F.D., Beachy, P.A., A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat. Genet. 33 (2003), 508–513.
39. Corbit, K.C., Aanstad, P., Singla, V., Norman, A.R., Stainier, D.Y.R., Reiter, J.F., Vertebrate Smoothened functions at the primary cilium. Nature 437 (2005), 1018–1021.
40. Corcoran, R.B., Scott, M.P., Oxysterols stimulate Sonic hedgehog signal transduction and proliferation of medulloblastoma cells. Proc. Natl. Acad. Sci. USA 103 (2006), 8408–8413.
41. Dai, P., Akimaru, H., Tanaka, Y., Maekawa, T., Nakafuku, M., Ishii, S., Sonic hedgehog-induced activation of the Gli1 promoter is mediated by GLI3. J. Biol. Chem. 274 (1999), 8143–8152.
42. Danial, C., Sarin, K.Y., Oro, A.E., Chang, A.L., An investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegib. Clin. Cancer Res. 22 (2016), 1325–1329.
43. Davies, J.P., Chen, F.W., Ioannou, Y.A., Transmembrane molecular pump activity of Niemann-Pick C1 protein. Science 290 (2000), 2295–2298.
44. Dellovade, T., Romer, J.T., Curran, T., Rubin, L.L., The hedgehog pathway and neurological disorders. Annu. Rev. Neurosci. 29 (2006), 539–563.
45. Dierks, C., Grbic, J., Zirlik, K., Beigi, R., Englund, N.P., Guo, G.R., Veelken, H., Engelhardt, M., Mertelsmann, R., Kelleher, J.F., et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat. Med. 13 (2007), 944–951.
46. Dierks, C., Beigi, R., Guo, G.R., Zirlik, K., Stegert, M.R., Manley, P., Trussell, C., Schmitt-Graeff, A., Landwerlin, K., Veelken, H., et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14 (2008), 238–249.
47. Dijkgraaf, G.J., Alicke, B., Weinmann, L., Januario, T., West, K., Modrusan, Z., Burdick, D., Goldsmith, R., Robarge, K., Sutherlin, D., et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 71 (2011), 435–444.
48. Dlugosz, A., Agrawal, S., Kirkpatrick, P., Vismodegib. Nat. Rev. Drug Discov. 11 (2012), 437–438.
49. Dockendorff, C., Nagiec, M.M., Weiwer, M., Buhrlage, S., Ting, A., Nag, P.P., Germain, A., Kim, H.J., Youngsaye, W., Scherer, C., et al. Macrocyclic hedgehog pathway inhibitors: optimization of cellular activity and mode of action studies. ACS Med. Chem. Lett. 3 (2012), 808–813.
50. Dorn, K.V., Hughes, C.E., Rohatgi, R., A smoothened-Evc2 complex transduces the hedgehog signal at primary cilia. Dev. Cell 23 (2012), 823–835.
51. Ellison, D.W., Dalton, J., Kocak, M., Nicholson, S.L., Fraga, C., Neale, G., Kenney, A.M., Brat, D.J., Perry, A., Yong, W.H., et al. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 121 (2011), 381–396.
52. Endoh-Yamagami, S., Evangelista, M., Wilson, D., Wen, X., Theunissen, J.W., Phamluong, K., Davis, M., Scales, S.J., Solloway, M.J., de Sauvage, F.J., et al. The mammalian Cos2 homolog Kif7 plays an essential role in modulating Hh signal transduction during development. Curr. Biol. 19 (2009), 1320–1326.
53. Ericson, J., Morton, S., Kawakami, A., Roelink, H., Jessell, T.M., Two critical periods of Sonic Hedgehog signaling required for the specification of motor neuron identity. Cell 87 (1996), 661–673.
54. Fei, D.L., Li, H., Kozul, C.D., Black, K.E., Singh, S., Gosse, J.A., DiRenzo, J., Martin, K.A., Wang, B., Hamilton, J.W., et al. Activation of Hedgehog signaling by the environmental toxicant arsenic may contribute to the etiology of arsenic-induced tumors. Cancer Res. 70 (2010), 1981–1988.
55. Ferruzzi, P., Mennillo, F., De Rosa, A., Giordano, C., Rossi, M., Benedetti, G., Magrini, R., Pericot Mohr, G., Miragliotta, V., Magnoni, L., et al. In vitro and in vivo characterization of a novel Hedgehog signaling antagonist in human glioblastoma cell lines. Int. J. Cancer, 131, 2012, 31.
56. Frank-Kamenetsky, M., Zhang, X.M., Bottega, S., Guicherit, O., Wichterle, H., Dudek, H., Bumcrot, D., Wang, F.Y., Jones, S., Shulok, J., et al. Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists. J. Biol., 1, 2002, 10.
57. Fumoto, K., Hoogenraad, C.C., Kikuchi, A., GSK-3beta-regulated interaction of BICD with dynein is involved in microtubule anchorage at centrosome. EMBO J. 25 (2006), 5670–5682.
58. Gailani, M.R., Stahle-Backdahl, M., Leffell, D.J., Glynn, M., Zaphiropoulos, P.G., Pressman, C., Unden, A.B., Dean, M., Brash, D.E., Bale, A.E., et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat. Genet. 14 (1996), 78–81.
59. Gajjar, A., Stewart, C.F., Ellison, D.W., Kaste, S., Kun, L.E., Packer, R.J., Goldman, S., Chintagumpala, M., Wallace, D., Takebe, N., et al. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin. Cancer Res. 19 (2013), 6305–6312.
60. Gajjar, A.J., Gururangan, S., Qaddoumi, I.A., Packer, R., Goldman, S., Prados, M., Desjardins, A., Fouladi, M., Takebe, N., Li, S., A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): a Pediatric Brain Tumor Consortium study (PBTC 25B). ASCO Annu. Meet. Proc., 31, 2013, 2035.
61. Gao, J., Graves, S., Koch, U., Liu, S., Jankovic, V., Buonamici, S., El Andaloussi, A., Nimer, S.D., Kee, B.L., Taichman, R., et al. Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell 4 (2009), 548–558.
62. Garcia-Gonzalo, F.R., Phua, S.C., Roberson, E.C., Garcia, G. 3rd, Abedin, M., Schurmans, S., Inoue, T., Reiter, J.F., Phosphoinositides regulate ciliary protein trafficking to modulate hedgehog signaling. Dev. Cell 34 (2015), 400–409.
63. Gendreau, S.B., Hawkins, D., Ho, C.P., Lewin, A., Lin, T., Merchant, A., Rowley, R.B., Wang, Q., Matsui, W., Fargnoli, J., Abstract B192: preclinical characterization of BMS-833923 (XL139), a hedgehog (HH) pathway inhibitor in early clinical development. Mol. Cancer Ther., 8, 2009, B192.
64. Geoerger, B., Aerts, I., Casanova, M., Chisholm, J.C., Hargrave, D.R., Leary, S., Ashley, D.M., Bouffet, E., MacDonald, T., Hurh, E., A phase I/II study of LDE225, a smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors. ASCO Annu. Meet. Proc., 30, 2012, 9519.
65. Gibson, P., Tong, Y.A., Robinson, G., Thompson, M.C., Currle, D.S., Eden, C., Kranenburg, T.A., Hogg, T., Poppleton, H., Martin, J., et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 468 (2010), 1095–1099.
66. Goldman, J., Eckhardt, S.G., Borad, M.J., Curtis, K.K., Hidalgo, M., Calvo, E., Ryan, D.P., Wirth, L.J., Parikh, A., Partyka, J., et al. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. Clin. Cancer Res. 21 (2015), 1002–1009.
67. Gorojankina, T., Hoch, L., Faure, H., Roudaut, H., Traiffort, E., Schoenfelder, A., Girard, N., Mann, A., Manetti, F., Solinas, A., et al. Discovery, molecular and pharmacological characterization of GSA-10, a novel small-molecule positive modulator of Smoothened. Mol. Pharmacol. 83 (2013), 1020–1029.
68. Graham, R.A., Lum, B.L., Cheeti, S., Jin, J.Y., Jorga, K., Von Hoff, D.D., Rudin, C.M., Reddy, J.C., Low, J.A., Lorusso, P.M., Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin. Cancer Res. 17 (2011), 2512–2520.
69. Hahn, H., Wicking, C., Zaphiropoulous, P.G., Gailani, M.R., Shanley, S., Chidambaram, A., Vorechovsky, I., Holmberg, E., Unden, A.B., Gillies, S., et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85 (1996), 841–851.
70. Hahn, H., Wojnowski, L., Zimmer, A.M., Hall, J., Miller, G., Zimmer, A., Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat. Med. 4 (1998), 619–622.
71. Han, Y., Shi, Q., Jiang, J., Multisite interaction with Sufu regulates Ci/Gli activity through distinct mechanisms in Hh signal transduction. Proc. Natl. Acad. Sci. USA 112 (2015), 6383–6388.
72. Harris, P.J., Speranza, G., Dansky Ullmann, C., Targeting embryonic signaling pathways in cancer therapy. Expert Opin. Ther. Targets 16 (2012), 131–145.
73. Hausmann, G., von Mering, C., Basler, K., The hedgehog signaling pathway: where did it come from?. PLoS Biol., 7, 2009, e1000146.
74. Haycraft, C.J., Banizs, B., Aydin-Son, Y., Zhang, Q., Michaud, E.J., Yoder, B.K., Gli2 and Gli3 localize to cilia and require the intraflagellar transport protein polaris for processing and function. PLoS Genet., 1, 2005, e53.
75. Hofmann, I., Stover, E.H., Cullen, D.E., Mao, J., Morgan, K.J., Lee, B.H., Kharas, M.G., Miller, P.G., Cornejo, M.G., Okabe, R., et al. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell 4 (2009), 559–567.
76. Hosoya, T., Arai, M.A., Koyano, T., Kowithayakorn, T., Ishibashi, M., Naturally occurring small-molecule inhibitors of hedgehog/GLI-mediated transcription. Chembiochem 9 (2008), 1082–1092.
77. Huang, S.H., He, J., Zhang, X.L., Bian, Y.H., Yang, L., Xie, G.R., Zhang, K.F., Tang, W.D., Stelter, A.A., Wang, Q., et al. Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis 27 (2006), 1334–1340.
78. Huang, P., Nedelcu, D., Watanabe, M., Jao, C., Kim, Y., Liu, J., Salic, A., Cellular cholesterol directly activates smoothened in hedgehog signaling. Cell 166 (2016), 1176–1187.
79. Hyman, J.M., Firestone, A.J., Heine, V.M., Zhao, Y., Ocasio, C.A., Han, K., Sun, M., Rack, P.G., Sinha, S., Wu, J.J., et al. Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc. Natl. Acad. Sci. USA 106 (2009), 14132–14137.
80. Iarrobino, A., Messina, J.L., Kudchadkar, R., Sondak, V.K., Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib. J. Am. Acad. Dermatol., 69, 2013, 023.
81. Incardona, J.P., Gaffield, W., Kapur, R.P., Roelink, H., The teratogenic Veratrum alkaloid cyclopamine inhibits Sonic hedgehog signal transduction. Development 125 (1998), 3553–3562.
82. Infante, P., Mori, M., Alfonsi, R., Ghirga, F., Aiello, F., Toscano, S., Ingallina, C., Siler, M., Cucchi, D., Po, A., et al. Gli1/DNA interaction is a druggable target for Hedgehog-dependent tumors. EMBO J. 34 (2015), 200–217.
83. Ingham, P.W., McMahon, A.P., Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 15 (2001), 3059–3087.
84. Ingham, P.W., Nakano, Y., Seger, C., Mechanisms and functions of Hedgehog signalling across the metazoa. Nat. Rev. Genet. 12 (2011), 393–406.
85. Irvine, D.A., Copland, M., Targeting hedgehog in hematologic malignancy. Blood 119 (2012), 2196–2204.
86. Jagani, Z., Dorsch, M., Warmuth, M., Hedgehog pathway activation in chronic myeloid leukemia. Cell Cycle 9 (2010), 3449–3456.
87. Jiang, K., Liu, Y., Fan, J., Zhang, J., Li, X.-A., Evers, B.M., Zhu, H., Jia, J., PI(4)P promotes phosphorylation and conformational change of smoothened through interaction with its C-terminal tail. PLoS Biol., 14, 2016, e1002375.
88. Jimeno, A., Weiss, G.J., Miller, W.H. Jr., Gettinger, S., Eigl, B.J., Chang, A.L., Dunbar, J., Devens, S., Faia, K., Skliris, G., et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin. Cancer Res. 19 (2013), 2766–2774.
89. Johnson, R.L., Rothman, A.L., Xie, J., Goodrich, L.V., Bare, J.W., Bonifas, J.M., Quinn, A.G., Myers, R.M., Cox, D.R., Epstein, E.H. Jr., et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272 (1996), 1668–1671.
90. Junker, J.P., Peterson, K.A., Nishi, Y., Mao, J., McMahon, A.P., van Oudenaarden, A., A predictive model of bifunctional transcription factor signaling during embryonic tissue patterning. Dev. Cell 31 (2014), 448–460.
91. Karhadkar, S.S., Bova, G.S., Abdallah, N., Dhara, S., Gardner, D., Maitra, A., Isaacs, J.T., Berman, D.M., Beachy, P.A., Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431 (2004), 707–712.
92. Kaye, S.B., Fehrenbacher, L., Holloway, R., Amit, A., Karlan, B., Slomovitz, B., Sabbatini, P., Fu, L., Yauch, R.L., Chang, I., et al. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin. Cancer Res. 18 (2012), 6509–6518.
93. Keeler, R.F., Teratogenic compounds of Veratrum californicum (Durand) X. Cyclopia in rabbits produced by cyclopamine. Teratology 3 (1970), 175–180.
94. Keeler, R.F., Teratogenic compounds of Veratrum californicum (Durand). XIV. Limb deformities produced by cyclopamine. Proc. Soc. Exp. Biol. Med. 142 (1973), 1287–1291.
95. Khan, A.A., Harrison, C.N., McLornan, D.P., Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase?. Br. J. Haematol. 170 (2015), 323–335.
96. Kieran, M., Geoerger, B., Casanova, M., Chisholm, J., Aerts, I., Bouffet, E., Brandes, A.A., Leary, S.E., Sullivan, M., Bailey, S., A phase 1/2 safety and preliminary efficacy study of sonidegib (LDE225), a hedgehog pathway inhibitor, in pediatric and adult patients with relapsed or refractory medulloblastoma and other solid tumors. Neuro-Oncology 15:Suppl 3 (2013), iii98–iii135.
97. Kim, J., Lee, J.J., Gardner, D., Beachy, P.A., Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc. Natl. Acad. Sci. USA 107 (2010), 13432–13437.
98. Kim, J., Tang, J.Y., Gong, R., Kim, J., Lee, J.J., Clemons, K.V., Chong, C.R., Chang, K.S., Fereshteh, M., Gardner, D., Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 17 (2010), 388–399.
99. Kim, J., Aftab, B.T., Tang, J.Y., Kim, D., Lee, A.H., Rezaee, M., Chen, B., King, E.M., Borodovsky, A., Riggins, G.J., et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 23 (2013), 23–34.
100. Kim, D.J., Kim, J., Spaunhurst, K., Montoya, J., Khodosh, R., Chandra, K., Fu, T., Gilliam, A., Molgo, M., Beachy, P.A., et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J. Clin. Oncol. 32 (2014), 745–751.
101. Kim, E.J., Sahai, V., Abel, E.V., Griffith, K.A., Greenson, J.K., Takebe, N., Khan, G.N., Blau, J.L., Craig, R., Balis, U.G., et al. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin. Cancer Res. 20 (2014), 5937–5945.
102. Kim, J., Hsia, E.Y., Brigui, A., Plessis, A., Beachy, P.A., Zheng, X., The role of ciliary trafficking in Hedgehog receptor signaling. Sci. Signal., 8, 2015, ra55.
103. Kimura, H., Ng, J.M., Curran, T., Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell 13 (2008), 249–260.
104. Ko, A.H., LoConte, N., Tempero, M.A., Walker, E.J., Kate Kelley, R., Lewis, S., Chang, W.C., Kantoff, E., Vannier, M.W., Catenacci, D.V., et al. A phase I study of FOLFIRINOX plus IPI-926, a hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma. Pancreas 45 (2016), 370–375.
105. Kogerman, P., Grimm, T., Kogerman, L., Krause, D., Unden, A.B., Sandstedt, B., Toftgard, R., Zaphiropoulos, P.G., Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of Gli-1. Nat. Cell Biol. 1 (1999), 312–319.
106. Kool, M., Korshunov, A., Remke, M., Jones, D.T.W., Schlanstein, M., Northcott, P.A., Cho, Y.-J., Koster, J., Schouten-van Meeteren, A., van Vuurden, D., et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 123 (2012), 473–484.
107. Lai, K., Kaspar, B.K., Gage, F.H., Schaffer, D.V., Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nat. Neurosci. 6 (2003), 21–27.
108. Lau, J., Kawahira, H., Hebrok, M., Hedgehog signaling in pancreas development and disease. Cell. Mol. Life Sci. 63 (2006), 642–652.
109. Lauth, M., Bergstrom, A., Shimokawa, T., Toftgard, R., Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc. Natl. Acad. Sci. USA 104 (2007), 8455–8460.
110. Lee, J., Platt, K.A., Censullo, P., Altaba, A.R.I., Gli1 is a target of Sonic hedgehog that induces ventral neural tube development. Development 124 (1997), 2537–2552.
111. Li, B., Giambelli, C., Tang, B., Winterbottom, E., Long, J., Jin, K., Wang, Z., Fei, D.L., Nguyen, D.M., Athar, M., et al. Arsenic attenuates GLI signaling, increasing or decreasing its transcriptional program in a context-dependent manner. Mol. Pharmacol. 89 (2016), 226–232.
112. Liem, K.F. Jr., He, M., Ocbina, P.J., Anderson, K.V., Mouse Kif7/Costal2 is a cilia-associated protein that regulates Sonic hedgehog signaling. Proc. Natl. Acad. Sci. USA 106 (2009), 13377–13382.
113. Lin, C., Yao, E., Wang, K., Nozawa, Y., Shimizu, H., Johnson, J.R., Chen, J.N., Krogan, N.J., Chuang, P.T., Regulation of Sufu activity by p66beta and Mycbp provides new insight into vertebrate Hedgehog signaling. Genes Dev. 28 (2014), 2547–2563.
114. Liu, Z., Li, T., Reinhold, M., Naski, M., MEK1–RSK2 contributes to hedgehog signaling by stabilizing GLI2 transcription factor and inhibiting ubiquitination. Oncogene 33 (2014), 65–73.
115. Liu, J., Zeng, H., Liu, A., The loss of Hh responsiveness by a non-ciliary Gli2 variant. Development 142 (2015), 1651–1660.
116. Liu, X., Pitarresi, J.R., Cuitino, M.C., Kladney, R.D., Woelke, S.A., Sizemore, G.M., Nayak, S.G., Egriboz, O., Schweickert, P.G., Yu, L., et al. Genetic ablation of Smoothened in pancreatic fibroblasts increases acinar-ductal metaplasia. Genes Dev. 30 (2016), 1943–1955.
117. LoRusso, P.M., Rudin, C.M., Reddy, J.C., Tibes, R., Weiss, G.J., Borad, M.J., Hann, C.L., Brahmer, J.R., Chang, I., Darbonne, W.C., et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin. Cancer Res. 17 (2011), 2502–2511.
118. Luchetti, G., Sircar, R., Kong, J.H., Nachtergaele, S., Sagner, A., Byrne, E.F., Covey, D.F., Siebold, C., Rohatgi, R., Cholesterol activates the G-protein coupled receptor Smoothened to promote morphogenetic signaling. Elife, 5, 2016, 20304.
119. Machold, R., Hayashi, S., Rutlin, M., Muzumdar, M.D., Nery, S., Corbin, J.G., Gritli-Linde, A., Dellovade, T., Porter, J.A., Rubin, L.L., et al. Sonic hedgehog is required for progenitor cell maintenance in telencephalic stem cell niches. Neuron 39 (2003), 937–950.
120. Mao, J., Barrow, J., McMahon, J., Vaughan, J., McMahon, A.P., An ES cell system for rapid, spatial and temporal analysis of gene function in vitro and in vivo. Nucleic Acids Res., 33, 2005, e155.
121. Martin, V., Carrillo, G., Torroja, C., Guerrero, I., The sterol-sensing domain of Patched protein seems to control Smoothened activity through Patched vesicular trafficking. Curr. Biol. 11 (2001), 601–607.
122. Martinelli, G., Oehler, V.G., Papayannidis, C., Courtney, R., Shaik, M.N., Zhang, X., O'Connell, A., McLachlan, K.R., Zheng, X., Radich, J., et al. Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. Lancet Haematol. 2 (2015), e339–e346.
123. Michelotti, G.A., Xie, G., Swiderska, M., Choi, S.S., Karaca, G., Kruger, L., Premont, R., Yang, L., Syn, W.K., Metzger, D., et al. Smoothened is a master regulator of adult liver repair. J. Clin. Invest. 123 (2013), 2380–2394.
124. Migden, M.R., Guminski, A., Gutzmer, R., Dirix, L., Lewis, K.D., Combemale, P., Herd, R.M., Kudchadkar, R., Trefzer, U., Gogov, S., et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 16 (2015), 716–728.
125. Milenkovic, L., Weiss, L.E., Yoon, J., Roth, T.L., Su, Y.S., Sahl, S.J., Scott, M.P., Moerner, W.E., Single-molecule imaging of Hedgehog pathway protein Smoothened in primary cilia reveals binding events regulated by Patched1. Proc. Natl. Acad. Sci. USA 112 (2015), 8320–8325.
126. Mills, L.D., Zhang, Y., Marler, R.J., Herreros-Villanueva, M., Zhang, L., Almada, L.L., Couch, F., Wetmore, C., Pasca di Magliano, M., Fernandez-Zapico, M.E., Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation. J. Biol. Chem. 288 (2013), 11786–11794.
127. Miyaji, T., Nakase, T., Iwasaki, M., Kuriyama, K., Tamai, N., Higuchi, C., Myoui, A., Tomita, T., Yoshikawa, H., Expression and distribution of transcripts for sonic hedgehog in the early phase of fracture repair. Histochem. Cell Biol. 119 (2003), 233–237.
128. Monzo, M., Moreno, I., Artells, R., Ibeas, R., Navarro, A., Moreno, J., Hernandez, R., Granell, M., Pie, J., Sonic hedgehog mRNA expression by real-time quantitative PCR in normal and tumor tissues from colorectal cancer patients. Cancer Lett. 233 (2006), 117–123.
129. Mukherjee, S., Frolova, N., Sadlonova, A., Novak, Z., Steg, A., Page, G.P., Welch, D.R., Lobo-Ruppert, S.M., Ruppert, J.M., Johnson, M.R., et al. Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol. Ther. 5 (2006), 674–683.
130. Mukhopadhyay, S., Wen, X., Ratti, N., Loktev, A., Rangell, L., Scales, S.J., Jackson, P.K., The ciliary G-protein-coupled receptor Gpr161 negatively regulates the Sonic hedgehog pathway via cAMP signaling. Cell 152 (2013), 210–223.
131. Munchhof, M.J., Li, Q., Shavnya, A., Borzillo, G.V., Boyden, T.L., Jones, C.S., LaGreca, S.D., Martinez-Alsina, L., Patel, N., Pelletier, K., et al. Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened. ACS Med. Chem. Lett. 3 (2011), 106–111.
132. Murone, M., Rosenthal, A., de Sauvage, F.J., Sonic hedgehog signaling by the patched-smoothened receptor complex. Curr. Biol. 9 (1999), 76–84.
133. Myers, B.R., Sever, N., Chong, Y.C., Kim, J., Belani, J.D., Rychnovsky, S., Bazan, J.F., Beachy, P.A., Hedgehog pathway modulation by multiple lipid binding sites on the smoothened effector of signal response. Dev. Cell 26 (2013), 346–357.
134. Nachtergaele, S., Mydock, L.K., Krishnan, K., Rammohan, J., Schlesinger, P.H., Covey, D.F., Rohatgi, R., Oxysterols are allosteric activators of the oncoprotein Smoothened. Nat. Chem. Biol. 8 (2012), 211–220.
135. Nachtergaele, S., Whalen, D.M., Mydock, L.K., Zhao, Z., Malinauskas, T., Krishnan, K., Ingham, P.W., Covey, D.F., Siebold, C., Rohatgi, R., Structure and function of the Smoothened extracellular domain in vertebrate Hedgehog signaling. Elife, 29, 2013, 01340.
136. Nedelcu, D., Liu, J., Xu, Y., Jao, C., Salic, A., Oxysterol binding to the extracellular domain of Smoothened in Hedgehog signaling. Nat. Chem. Biol. 9 (2013), 557–564.
137. Northcott, P.A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C.G., Mack, S., Bouffet, E., Clifford, S.C., Hawkins, C.E., French, P., et al. Medulloblastoma comprises four distinct molecular variants. J. Clin. Oncol. 29 (2011), 1408–1414.
138. Nusslein-Volhard, C., Wieschaus, E., Mutations affecting segment number and polarity in Drosophila. Nature 287 (1980), 795–801.
139. Ochoa, B., Syn, W.K., Delgado, I., Karaca, G.F., Jung, Y., Wang, J., Zubiaga, A.M., Fresnedo, O., Omenetti, A., Zdanowicz, M., Hedgehog signaling is critical for normal liver regeneration after partial hepatectomy in mice. Hepatology 51 (2010), 1712–1723.
140. Ohashi, T., Oguro, Y., Tanaka, T., Shiokawa, Z., Tanaka, Y., Shibata, S., Sato, Y., Yamakawa, H., Hattori, H., Yamamoto, Y., et al. Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility. Bioorg. Med. Chem. 20 (2012), 5507–5517.
141. Olive, K.P., Jacobetz, M.A., Davidson, C.J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M.A., Caldwell, M.E., Allard, D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324 (2009), 1457–1461.
142. Pan, Y., Wang, B., A novel protein-processing domain in Gli2 and Gli3 differentially blocks complete protein degradation by the proteasome. J. Biol. Chem. 282 (2007), 10846–10852.
143. Pan, Y., Bai, C.B., Joyner, A.L., Wang, B., Sonic hedgehog signaling regulates Gli2 transcriptional activity by suppressing its processing and degradation. Mol. Cell Biol. 26 (2006), 3365–3377.
144. Pan, S., Wu, X., Jiang, J., Gao, W., Wan, Y., Cheng, D., Han, D., Liu, J., Englund, N.P., Wang, Y., et al. Discovery of NVP-LDE225, a potent and selective smoothened antagonist. ACS Med. Chem. Lett. 1 (2010), 130–134.
145. Park, H.L., Bai, C., Platt, K.A., Matise, M.P., Beeghly, A., Hui, C.C., Nakashima, M., Joyner, A.L., Mouse Gli1 mutants are viable but have defects in SHH signaling in combination with a Gli2 mutation. Development 127 (2000), 1593–1605.
146. Peluso, M.O., Campbell, V.T., Harari, J.A., Tibbitts, T.T., Proctor, J.L., Whitebread, N., Conley, J.M., White, K.F., Kutok, J.L., Read, M.A., et al. Impact of the Smoothened inhibitor, IPI-926, on smoothened ciliary localization and Hedgehog pathway activity. PLoS One, 9, 2014, e90534.
147. Peng, T., Frank, D.B., Kadzik, R.S., Morley, M.P., Rathi, K.S., Wang, T., Zhou, S., Cheng, L., Lu, M.M., Morrisey, E.E., Hedgehog actively maintains adult lung quiescence and regulates repair and regeneration. Nature 526 (2015), 578–582.
148. Peterson, K.A., Nishi, Y., Ma, W., Vedenko, A., Shokri, L., Zhang, X., McFarlane, M., Baizabal, J.M., Junker, J.P., van Oudenaarden, A., et al. Neural-specific Sox2 input and differential Gli-binding affinity provide context and positional information in Shh-directed neural patterning. Genes Dev. 26 (2012), 2802–2816.
149. Petrova, E., Rios-Esteves, J., Ouerfelli, O., Glickman, J.F., Resh, M.D., Inhibitors of hedgehog acyltransferase block sonic hedgehog signaling. Nat. Chem. Biol. 9 (2013), 247–249.
150. Peukert, S., He, F., Dai, M., Zhang, R., Sun, Y., Miller-Moslin, K., McEwan, M., Lagu, B., Wang, K., Yusuff, N., et al. Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem 8 (2013), 1261–1265.
151. Pola, R., Ling, L.E., Silver, M., Corbley, M.J., Kearney, M., Blake Pepinsky, R., Shapiro, R., Taylor, F.R., Baker, D.P., Asahara, T., et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat. Med. 7 (2001), 706–711.
152. Raffel, C., Jenkins, R.B., Frederick, L., Hebrink, D., Alderete, B., Fults, D.W., James, C.D., Sporadic medulloblastomas contain PTCH mutations. Cancer Res. 57 (1997), 842–845.
153. Rana, R., Carroll, C.E., Lee, H.-J., Bao, J., Marada, S., Grace, C.R.R., Guibao, C.D., Ogden, S.K., Zheng, J.J., Structural insights into the role of the Smoothened cysteine-rich domain in Hedgehog signalling. Nat. Commun., 4, 2013, 2965.
154. Reifenberger, J., Wolter, M., Weber, R.G., Megahed, M., Ruzicka, T., Lichter, P., Reifenberger, G., Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 58 (1998), 1798–1803.
155. Reifenberger, J., Wolter, M., Knobbe, C.B., Kohler, B., Schonicke, A., Scharwachter, C., Kumar, K., Blaschke, B., Ruzicka, T., Reifenberger, G., Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br. J. Dermatol. 152 (2005), 43–51.
156. Rhim, A.D., Oberstein, P.E., Thomas, D.H., Mirek, E.T., Palermo, C.F., Sastra, S.A., Dekleva, E.N., Saunders, T., Becerra, C.P., Tattersall, I.W., Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25 (2014), 735–747.
157. Riobo, N.A., Lu, K., Ai, X., Haines, G.M., Emerson, C.P. Jr., Phosphoinositide 3-kinase and Akt are essential for sonic hedgehog signaling. Proc. Natl. Acad. Sci. USA 103 (2006), 4505–4510.
158. Robarge, K.D., Brunton, S.A., Castanedo, G.M., Cui, Y., Dina, M.S., Goldsmith, R., Gould, S.E., Guichert, O., Gunzner, J.L., Halladay, J., et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg. Med. Chem. Lett. 19 (2009), 5576–5581.
159. Roberts, B., Casillas, C., Alfaro, A.C., Jagers, C., Roelink, H., Patched1 and Patched2 inhibit Smoothened non-cell autonomously. Elife, 23, 2016, 17634.
160. Robinson, G.W., Orr, B.A., Wu, G., Gururangan, S., Lin, T., Qaddoumi, I., Packer, R.J., Goldman, S., Prados, M.D., Desjardins, A., et al. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. J. Clin. Oncol. 33 (2015), 2646–2654.
161. Rodon, J., Tawbi, H.A., Thomas, A.L., Stoller, R.G., Turtschi, C.P., Baselga, J., Sarantopoulos, J., Mahalingam, D., Shou, Y., Moles, M.A., et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin. Cancer Res. 20 (2014), 1900–1909.
162. Rohatgi, R., Milenkovic, L., Scott, M.P., Patched1 regulates Hedgehog signaling at the primary cilium. Science 317 (2007), 372–376.
163. Rohatgi, R., Milenkovic, L., Corcoran, R.B., Scott, M.P., Hedgehog signal transduction by Smoothened: pharmacologic evidence for a 2-step activation process. Proc. Natl. Acad. Sci. USA 106 (2009), 3196–3201.
164. Romer, J.T., Kimura, H., Magdaleno, S., Sasai, K., Fuller, C., Baines, H., Connelly, M., Stewart, C.F., Gould, S., Rubin, L.L., et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 6 (2004), 229–240.
165. Roudaut, H., Traiffort, E., Gorojankina, T., Vincent, L., Faure, H., Schoenfelder, A., Mann, A., Manetti, F., Solinas, A., Taddei, M., et al. Identification and mechanism of action of the Acylguanidine MRT-83, a novel potent smoothened antagonist. Mol. Pharmacol. 79 (2011), 453–460.
166. Rubin, L.L., de Sauvage, F.J., Targeting the Hedgehog pathway in cancer. Nat. Rev. Drug Discov. 5 (2006), 1026–1033.
167. Rudin, C.M., Hann, C.L., Laterra, J., Yauch, R.L., Callahan, C.A., Fu, L., Holcomb, T., Stinson, J., Gould, S.E., Coleman, B., et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med. 361 (2009), 1173–1178.
168. Ruiz i Altaba, A., Combinatorial Gli gene function in floor plate and neuronal inductions by Sonic hedgehog. Development 125 (1998), 2203–2212.
169. Rusert, J.M., Wu, X., Eberhart, C.G., Taylor, M.D., Wechsler-Reya, R.J., SnapShot: medulloblastoma. Cancer Cell, 26, 2014, 940.
170. Sadarangani, A., Pineda, G., Lennon, K.M., Chun, H.-J., Shih, A., Schairer, A.E., Goff, D.J., Prashad, S.L., Geron, I., Wall, R., GLI2 inhibition abrogates human leukemia stem cell dormancy. J. Transl. Med., 13, 2015, 98.
171. Sasaki, H., Nishizaki, Y., Hui, C.C., Nakafuku, M., Kondoh, H., Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as primary mediators of Shh signaling. Development 126 (1999), 3915–3924.
172. Schuller, U., Heine, V.M., Mao, J., Kho, A.T., Dillon, A.K., Han, Y.G., Huillard, E., Sun, T., Ligon, A.H., Qian, Y., et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 14 (2008), 123–134.
173. Sekulic, A., Migden, M.R., Oro, A.E., Dirix, L., Lewis, K.D., Hainsworth, J.D., Solomon, J.A., Yoo, S., Arron, S.T., Friedlander, P.A., et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N. Engl. J. Med. 366 (2012), 2171–2179.
174. Sever, N., Mann, R.K., Xu, L., Snell, W.J., Hernandez-Lara, C.I., Porter, N.A., Beachy, P.A., Endogenous B-ring oxysterols inhibit the Hedgehog component Smoothened in a manner distinct from cyclopamine or side-chain oxysterols. Proc. Natl. Acad. Sci. USA 113 (2016), 5904–5909.
175. Sharpe, H.J., Pau, G., Dijkgraaf, G.J., Basset-Seguin, N., Modrusan, Z., Januario, T., Tsui, V., Durham, A.B., Dlugosz, A.A., Haverty, P.M., et al. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell 27 (2015), 327–341.
176. Sharpe, H.J., Wang, W., Hannoush, R.N., de Sauvage, F.J., Regulation of the oncoprotein Smoothened by small molecules. Nat. Chem. Biol. 11 (2015), 246–255.
177. Shi, X., Zhang, Z., Zhan, X., Cao, M., Satoh, T., Akira, S., Shpargel, K., Magnuson, T., Li, Q., Wang, R., et al. An epigenetic switch induced by Shh signalling regulates gene activation during development and medulloblastoma growth. Nat. Commun., 5, 2014, 5425.
178. Shin, K., Lee, J., Guo, N., Kim, J., Lim, A., Qu, L., Mysorekar, I.U., Beachy, P.A., Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature 472 (2011), 110–114.
179. Shin, K., Lim, A., Zhao, C., Sahoo, D., Pan, Y., Spiekerkoetter, E., Liao, J.C., Beachy, P.A., Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. Cancer Cell 26 (2014), 521–533.
180. Shou, Y., Robinson, D.M., Amakye, D.D., Rose, K.L., Cho, Y.J., Ligon, K.L., Sharp, T., Haider, A.S., Bandaru, R., Ando, Y., et al. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Clin. Cancer Res. 21 (2015), 585–593.
181. Sillibourne, J.E., Milne, D.M., Takahashi, M., Ono, Y., Meek, D.W., Centrosomal anchoring of the protein kinase CK1delta mediated by attachment to the large, coiled-coil scaffolding protein CG-NAP/AKAP450. J. Mol. Biol. 322 (2002), 785–797.
182. Sinha, S., Chen, J.K., Purmorphamine activates the Hedgehog pathway by targeting Smoothened. Nat. Chem. Biol. 2 (2006), 29–30.
183. Siu, L.L., Papadopoulos, K.P., Alberts, S.R., Taylor, S., Patnaik, A., Chen, E.X., Tolcher, A., Vakkalaguada, B., Lang, L., Ahlers, C., et al. Abstract A55: a first-in-human, phase I study of an oral hedgehog pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. Mol. Cancer Ther., 8, 2009, A55.
184. Smith, M.J., Beetz, C., Williams, S.G., Bhaskar, S.S., O'Sullivan, J., Anderson, B., Daly, S.B., Urquhart, J.E., Bholah, Z., Oudit, D., et al. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J. Clin. Oncol. 32 (2014), 4155–4161.
185. Stanton, B.Z., Peng, L.F., Maloof, N., Nakai, K., Wang, X., Duffner, J.L., Taveras, K.M., Hyman, J.M., Lee, S.W., Koehler, A.N., et al. A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat. Chem. Biol. 5 (2009), 154–156.
186. Stone, D.M., Murone, M., Luoh, S., Ye, W., Armanini, M.P., Gurney, A., Phillips, H., Brush, J., Goddard, A., de Sauvage, F.J., et al. Characterization of the human suppressor of fused, a negative regulator of the zinc-finger transcription factor Gli. J. Cell Sci. 112 (1999), 4437–4448.
187. Strutt, H., Thomas, C., Nakano, Y., Stark, D., Neave, B., Taylor, A.M., Ingham, P.W., Mutations in the sterol-sensing domain of Patched suggest a role for vesicular trafficking in Smoothened regulation. Curr. Biol. 11 (2001), 608–613.
188. Taipale, J., Chen, J.K., Cooper, M.K., Wang, B., Mann, R.K., Milenkovic, L., Scott, M.P., Beachy, P.A., Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 406 (2000), 1005–1009.
189. Taipale, J., Cooper, M.K., Maiti, T., Beachy, P.A., Patched acts catalytically to suppress the activity of Smoothened. Nature 418 (2002), 892–897.
190. Tang, J.Y., Xiao, T.Z., Oda, Y., Chang, K.S., Shpall, E., Wu, A., So, P.L., Hebert, J., Bikle, D., Epstein, E.H. Jr., Vitamin D3 inhibits hedgehog signaling and proliferation in murine basal cell carcinomas. Cancer Prev. Res. 4 (2011), 744–751.
191. Tang, J.Y., Mackay-Wiggan, J.M., Aszterbaum, M., Yauch, R.L., Lindgren, J., Chang, K., Coppola, C., Chanana, A.M., Marji, J., Bickers, D.R., et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N. Engl. J. Med. 366 (2012), 2180–2188.
192. Tang, Y., Gholamin, S., Schubert, S., Willardson, M.I., Lee, A., Bandopadhayay, P., Bergthold, G., Masoud, S., Nguyen, B., Vue, N., et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat. Med. 20 (2014), 732–740.
193. Tao, H., Jin, Q., Koo, D.I., Liao, X., Englund, N.P., Wang, Y., Ramamurthy, A., Schultz, P.G., Dorsch, M., Kelleher, J., et al. Small molecule antagonists in distinct binding modes inhibit drug-resistant mutant of smoothened. Chem. Biol. 18 (2011), 432–437.
194. Tay, S.Y., Ingham, P.W., Roy, S., A homologue of the Drosophila kinesin-like protein Costal2 regulates Hedgehog signal transduction in the vertebrate embryo. Development 132 (2005), 625–634.
195. Tempé, D., Casas, M., Karaz, S., Blanchet-Tournier, M.-F., Concordet, J.-P., Multisite protein kinase A and glycogen synthase kinase 3β phosphorylation leads to Gli3 ubiquitination by SCFβTrCP. Mol. Cell. Biol. 26 (2006), 4316–4326.
196. Thayer, S.P., di Magliano, M.P., Heiser, P.W., Nielsen, C.M., Roberts, D.J., Lauwers, G.Y., Qi, Y.P., Gysin, S., Fernandez-del Castillo, C., Yajnik, V., et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425 (2003), 851–856.
197. Thomas, N.A., Koudijs, M., van Eeden, F.J., Joyner, A.L., Yelon, D., Hedgehog signaling plays a cell-autonomous role in maximizing cardiac developmental potential. Development 135 (2008), 3789–3799.
198. Tibes, R., Mesa, R.A., Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies. J. Hematol. Oncol., 7, 2014, 18.
199. Tostar, U., Malm, C.J., Meis-Kindblom, J.M., Kindblom, L.G., Toftgard, R., Unden, A.B., Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development. J. Pathol. 208 (2006), 17–25.
200. Tremblay, M.R., Lescarbeau, A., Grogan, M.J., Tan, E., Lin, G., Austad, B.C., Yu, L.C., Behnke, M.L., Nair, S.J., Hagel, M., et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J. Med. Chem. 52 (2009), 4400–4418.
201. Unden, A.B., Holmberg, E., Lundh-Rozell, B., Stahle-Backdahl, M., Zaphiropoulos, P.G., Toftgard, R., Vorechovsky, I., Mutations in the human homologue of Drosophila patched (PTCH) in basal cell carcinomas and the Gorlin syndrome: different in vivo mechanisms of PTCH inactivation. Cancer Res. 56 (1996), 4562–4565.
202. Varnat, F., Duquet, A., Malerba, M., Zbinden, M., Mas, C., Gervaz, P., Ruiz i Altaba, A., Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol. Med. 1 (2009), 338–351.
203. Vokes, S.A., Ji, H., Wong, W.H., McMahon, A.P., A genome-scale analysis of the cis-regulatory circuitry underlying sonic hedgehog-mediated patterning of the mammalian limb. Genes Dev. 22 (2008), 2651–2663.
204. Von Hoff, D.D., LoRusso, P.M., Rudin, C.M., Reddy, J.C., Yauch, R.L., Tibes, R., Weiss, G.J., Borad, M.J., Hann, C.L., Brahmer, J.R., et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N. Engl. J. Med. 361 (2009), 1164–1172.
205. Wallace, V.A., Raff, M.C., A role for Sonic hedgehog in axon-to-astrocyte signalling in the rodent optic nerve. Development 126 (1999), 2901–2909.
206. Wang, B., Li, Y., Evidence for the direct involvement of {beta}TrCP in Gli3 protein processing. Proc. Natl. Acad. Sci. USA 103 (2006), 33–38.
207. Wang, Y., Zhou, Z., Walsh, C.T., McMahon, A.P., Selective translocation of intracellular Smoothened to the primary cilium in response to Hedgehog pathway modulation. Proc. Natl. Acad. Sci. USA 106 (2009), 2623–2628.
208. Wang, J., Lu, J., Bond, M.C., Chen, M., Ren, X.R., Lyerly, H.K., Barak, L.S., Chen, W., Identification of select glucocorticoids as Smoothened agonists: potential utility for regenerative medicine. Proc. Natl. Acad. Sci. USA 107 (2010), 9323–9328.
209. Wang, Y., Arvanites, A.C., Davidow, L., Blanchard, J., Lam, K., Yoo, J.W., Coy, S., Rubin, L.L., McMahon, A.P., Selective identification of hedgehog pathway antagonists by direct analysis of smoothened ciliary translocation. ACS Chem. Biol. 7 (2012), 1040–1048.
210. Wang, Y., Davidow, L., Arvanites, A.C., Blanchard, J., Lam, K., Xu, K., Oza, V., Yoo, J.W., Ng, J.M., Curran, T., et al. Glucocorticoid compounds modify smoothened localization and hedgehog pathway activity. Chem. Biol. 19 (2012), 972–982.
211. Wang, Y., Ding, Q., Yen, C.J., Xia, W., Izzo, J.G., Lang, J.Y., Li, C.W., Hsu, J.L., Miller, S.A., Wang, X., et al. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 21 (2012), 374–387.
212. Wang, C., Wu, H., Katritch, V., Han, G.W., Huang, X.-P., Liu, W., Siu, F.Y., Roth, B.L., Cherezov, V., Stevens, R.C., Structure of the human smoothened receptor bound to an antitumour agent. Nature 497 (2013), 338–343.
213. Wang, C., Wu, H., Evron, T., Vardy, E., Han, G.W., Huang, X.-P., Hufeisen, S.J., Mangano, T.J., Urban, D.J., Katritch, V., et al. Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs. Nat. Commun., 5, 2014, 4355.
214. Wang, J., Cao, J., Dickson, A.L., Poss, K.D., Epicardial regeneration is guided by cardiac outflow tract and Hedgehog signalling. Nature 522 (2015), 226–230.
215. Watkins, D.N., Berman, D.M., Burkholder, S.G., Wang, B., Beachy, P.A., Baylin, S.B., Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 422 (2003), 313–317.
216. Weierstall, U., James, D., Wang, C., White, T.A., Wang, D., Liu, W., Spence, J.C.H., Bruce Doak, R., Nelson, G., Fromme, P., et al. Lipidic cubic phase injector facilitates membrane protein serial femtosecond crystallography. Nat. Commun., 5, 2014, 3309.
217. Williams, J.A., Guicherit, O.M., Zaharian, B.I., Xu, Y., Chai, L., Wichterle, H., Kon, C., Gatchalian, C., Porter, J.A., Rubin, L.L., et al. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. Proc. Natl. Acad. Sci. USA 100 (2003), 4616–4621.
218. Williams, C.H., Hempel, J.E., Hao, J., Frist, A.Y., Williams, M.M., Fleming, J.T., Sulikowski, G.A., Cooper, M.K., Chiang, C., Hong, C.C., An in vivo chemical genetic screen identifies phosphodiesterase 4 as a pharmacological target for hedgehog signaling inhibition. Cell Rep. 11 (2015), 43–50.
219. Wilson, C.W., Chuang, P.T., Mechanism and evolution of cytosolic Hedgehog signal transduction. Development 137 (2010), 2079–2094.
220. Wilson, C.W., Chen, M.-H., Chuang, P.-T., Smoothened adopts multiple active and inactive conformations capable of trafficking to the primary cilium. PLoS One, 4, 2009, e5182.
221. Wu, X., Ding, S., Ding, Q., Gray, N.S., Schultz, P.G., A small molecule with osteogenesis-inducing activity in multipotent mesenchymal progenitor cells. J. Am. Chem. Soc. 124 (2002), 14520–14521.
222. Wu, X., Walker, J., Zhang, J., Ding, S., Schultz, P.G., Purmorphamine induces osteogenesis by activation of the hedgehog signaling pathway. Chem. Biol. 11 (2004), 1229–1238.
223. Wu, V.M., Chen, S.C., Arkin, M.R., Reiter, J.F., Small molecule inhibitors of Smoothened ciliary localization and ciliogenesis. Proc. Natl. Acad. Sci. USA 109 (2012), 13644–13649.
224. Xie, J., Murone, M., Luoh, S.M., Ryan, A., Gu, Q., Zhang, C., Bonifas, J.M., Lam, C.W., Hynes, M., Goddard, A., et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 391 (1998), 90–92.
225. Xu, L.B., Mirnics, K., Bowman, A.B., Liu, W., Da, J., Porter, N.A., Korade, Z., DHCEO accumulation is a critical mediator of pathophysiology in a Smith-Lemli-Opitz syndrome model. Neurobiol. Dis. 45 (2012), 923–929.
226. Yang, H., Xiang, J., Wang, N., Zhao, Y., Hyman, J., Li, S., Jiang, J., Chen, J.K., Yang, Z., Lin, S., Converse conformational control of smoothened activity by structurally related small molecules. J. Biol. Chem. 284 (2009), 20876–20884.
227. Yang, C.P., Chen, W.L., Chen, Y.B., Jiang, J., Smoothened transduces Hedgehog signal by forming a complex with Evc/Evc2. Cell Res. 22 (2012), 1593–1604.
228. Yauch, R.L., Gould, S.E., Scales, S.J., Tang, T., Tian, H., Ahn, C.P., Marshall, D., Fu, L., Januario, T., Kallop, D., et al. A paracrine requirement for hedgehog signalling in cancer. Nature 455 (2008), 406–410.
229. Yauch, R.L., Dijkgraaf, G.J., Alicke, B., Januario, T., Ahn, C.P., Holcomb, T., Pujara, K., Stinson, J., Callahan, C.A., Tang, T., et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326 (2009), 572–574.
230. Ye, F., Breslow, D.K., Koslover, E.F., Spakowitz, A.J., Nelson, W.J., Nachury, M.V., Single molecule imaging reveals a major role for diffusion in the exploration of ciliary space by signaling receptors. Elife, 2, 2013, e00654.
231. Zhang, X., Harrington, N., Moraes, R.C., Wu, M.F., Hilsenbeck, S.G., Lewis, M.T., Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo). Breast Cancer Res. Treat. 115 (2009), 505–521.
232. Zhang, Y., Fu, L., Qi, X., Zhang, Z., Xia, Y., Jia, J., Jiang, J., Zhao, Y., Wu, G., Structural insight into the mutual recognition and regulation between Suppressor of Fused and Gli/Ci. Nat. Commun., 4, 2013, 2608.
233. Zhao, C., Chen, A., Jamieson, C.H., Fereshteh, M., Abrahamsson, A., Blum, J., Kwon, H.Y., Kim, J., Chute, J.P., Rizzieri, D., et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458 (2009), 776–779.
234. Zhao, H., Feng, J., Seidel, K., Shi, S., Klein, O., Sharpe, P., Chai, Y., Secretion of shh by a neurovascular bundle niche supports mesenchymal stem cell homeostasis in the adult mouse incisor. Cell Stem Cell 14 (2014), 160–173.